Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

imvamune

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2015
2015
INTRODUCTION Previous research shows immune response to vaccination differs by sex but this has not been explored for IMVAMUNE, a… Expand
Is this relevant?
2013
2013
To support the licensure of a new and safer vaccine to protect people against smallpox, a monkeypox model of infection in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2013
2013
INTRODUCTION Reintroduction of Variola major as an agent of bioterrorism remains a concern. A shortened dosing schedule of… Expand
Is this relevant?
2011
2011
The 2003 monkeypox virus (MPXV) outbreak and subsequent laboratory studies demonstrated that the black-tailed prairie dog is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
IMVAMUNE is a Modified Vaccinia Ankara (MVA)-based virus that is being developed as a safer 3rd generation smallpox vaccine. In… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
Is this relevant?
2009
2009
Infection of rabbits with aerosolized rabbitpox virus (RPXV) produces a disease similar to monkeypox and smallpox in humans and… Expand
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2008
2008
  • Taff Jones
  • Current opinion in molecular therapeutics
  • 2008
  • Corpus ID: 26731823
Bavarian Nordic is developing IMVAMUNE, which is based on a live attenuated modified vaccinia Ankara virus, for the potential… Expand
Is this relevant?
2007
2007
Smallpox vaccination with replication deficient vaccinia strains such as Modified Vaccinia Ankara (MVA) may induce protective… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A Phase I trial was performed to investigate the safety and immunogenicity of the third generation smallpox vaccine MVA-BN… Expand
Is this relevant?